Bradykinesia News and Research

RSS

Safinamide significantly improved motor function in patients with advanced Parkinson's disease

Safinamide significantly improved motor function in patients with advanced Parkinson's disease

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, and its partner Newron Pharmaceuticals SpA has announced that the first Phase III trial of investigational agent safinamide as adjunctive therapy to levodopa (study 016) met its primary endpoint by increasing daily "ON" time in mid- to late-stage Parkinson's disease patients with motor fluctuations by 1.3 hours.

5 Feb 2009

Discovery provides model for Alzheimer's breakthrough

Discovery provides model for Alzheimer's breakthrough

Sydney researchers have made a major breakthrough that will lead to a greater understanding of the causes of and treatments for neurodegenerative diseases.

24 Sep 2008

FDA approves skin patch designed to treat symptoms of early Parkinson's disease

FDA approves skin patch designed to treat symptoms of early Parkinson's disease

Rotigotine is a drug not previously approved in the United States. Neupro is the first transdermal patch approved for the treatment of symptoms of Parkinson's disease.

10 May 2007

CleveMed receives approval to market motor assessment system

CleveMed receives approval to market motor assessment system

Cleveland Medical Devices has received Food and Drug Administration (FDA) clearance to market Kinesia, a quantitative motor assessment system.

2 May 2007

Alzheimer's disease may be more common than previously recognized

Alzheimer's disease may be more common than previously recognized

A study published in the January issue of the Annals of Neurology found that neurofibrillary tangles in the substantia nigra, a part of the brain that is subject to cell loss in Parkinson's disease, are associated with gait impairment in older persons with and without dementia.

25 Jan 2006

Family experience guides Alzheimer’s research

Family experience guides Alzheimer’s research

After watching his father struggle with and ultimately succumb to Alzheimer’s disease, ASU professor Michael Sierks shifted his research focus from starch hydrolyzing to neurodegenerative diseases.

18 Nov 2004

Exercise protects brain cells affected by Parkinson's

Exercise protects brain cells affected by Parkinson's

In an animal model of Parkinson's, exercise prevents degeneration of nerve cells that are normally impaired or destroyed by the disease, according to University of Pittsburgh researchers.

24 Oct 2004

Gene mutation causes Parkinson's disease in some families

Gene mutation causes Parkinson's disease in some families

An international research team, led by scientists at the National Institute on Aging (NIA), has discovered a gene, which when mutated, causes Parkinson's disease in some families.

22 Oct 2004

Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net.

To start a conversation, please log into your AZoProfile account first, or create a new account.

Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content.

A few things you need to know before we start. Please read and accept to continue.

Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
Large Language Models can make mistakes. Consider checking important information.

I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements.

Please check the box above to proceed.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.